Dercum Disease (Adiposis Dolorosa, Investigational Adjunct)
Investigational adjunct for painful lipomatous nodules in Dercum disease; analgesics, weight management, surgical excision of selected painful nodules, and lidocaine infusion remain investigational themselves; no FDA-approved disease-modifying therapy.
Patienten-Zusammenfassung
- Ist dies FDA-zugelassen fuer diese Anwendung?
- Not FDA-cleared for Dercum disease (adiposis dolorosa). FDA cleared medicinal leeches only for venous congestion in microsurgical reconstruction (K040187, June 2004). Use here is Tier C investigational.
- Welche Evidenz existiert?
- Tier C (investigational). No controlled trials. Dercum disease is poorly understood. Evidence-based first-line management is multimodal — analgesia (NSAIDs, neuropathic-pain medications like pregabalin or duloxetine), weight management, physical therapy, mental health support, and for selected painful lipomatous nodules surgical excision or liposuction. Some case reports describe response to lidocaine infusions or low-dose ketamine.
- Hauptrisiken
- Bleeding from each bite site for 6 to 10 hours after the leech detaches
- Iron-deficiency anemia from cumulative blood loss across multiple sessions
- Aeromonas hydrophila wound infection from leech gut bacteria (uncommon outside reconstructive surgery, but possible)
- Allergic reaction to leech saliva (rare; ranges from local itching to anaphylaxis)
- Permanent Y-shaped bite-mark scars or hyperpigmentation at attachment sites
- Local pain, bruising, swelling, or itching for 1 to 3 days after each session
- Bleeding into lipomatous tissue at bite sites
- Limited improvement in widespread pain from focal interventions
- Wer dies nicht in Betracht ziehen sollte
- Patients who have not tried structured analgesic therapy including neuropathic-pain medications
- Patients with very painful or rapidly growing nodules (consider surgical excision for those)
- Patients without a formal Dercum diagnosis (the condition is rare and frequently misdiagnosed)
- Anyone on blood thinners such as warfarin, apixaban, rivaroxaban, dabigatran, heparin, or daily aspirin used for medical reasons
- People with hemophilia or any other inherited bleeding disorder
- Patients with severe anemia (hemoglobin under 10 g/dL)
- People with an active infection at the planned application site
- Was Sie Ihren Kliniker fragen sollten
- Has my diagnosis of Dercum been confirmed and other causes of painful nodules excluded?
- Have I tried gabapentin, pregabalin, duloxetine, or other neuropathic-pain medications?
- Has surgical excision been considered for the most painful nodules?
- What is the published evidence base for leeches in Dercum disease?
- How will success be measured — pain score, quality of life, both?
- What is the plan if I do not respond?
- Wann dringende medizinische Versorgung suchen
- Bleeding from a bite site that soaks through more than one dressing per hour
- Bleeding that continues more than 24 hours after the leech detached
- Spreading redness, warmth, swelling, pus, or red streaks around any bite site
- Fever over 38.0 C / 100.4 F, chills, or feeling suddenly unwell after a session
- Hives, facial or tongue swelling, throat tightness, or any difficulty breathing
- Sudden weakness, dizziness, fast heart rate, or fainting (possible severe blood loss)
- Sudden severe enlargement, hardening, or fixation of a nodule (consider sarcoma or other malignancy)
- New systemic symptoms — weight loss, fever, night sweats
Was dies NICHT bedeutet
- It does not mean leech therapy is FDA-cleared for Dercum disease — the only FDA clearance is venous congestion in microsurgical reconstruction (K040187, June 2004).
- It does not address the (poorly understood) underlying pathology.
- It does not replace neuropathic-pain medications, weight management, or surgical excision of focal painful nodules.
- It does not have controlled-trial evidence.
- It does not differentiate Dercum from other causes of painful soft tissue masses.
Sicherheits-Querverweise
Clinical Profile
- Category
- other
- ICD-10
- E88.2
- Safety tier
- medium
Evidence Summary
Dercum disease (adiposis dolorosa) is a rare disorder of painful multiple subcutaneous lipomatous masses, predominantly in obese women, with associated fatigue, cognitive complaints, and depression. Etiology is unclear; theories include adipose-tissue inflammation, sympathetic dysregulation, and nerve compression. There is no FDA-approved disease-modifying therapy. Evidence base is weak across all options: analgesics (often including opioids for severe disease), weight management, surgical excision of selected most-painful nodules, and intravenous lidocaine infusion have been reported with variable response. No published controlled trials of hirudotherapy exist for Dercum disease. Periodic local application near (not on) painful nodules has been mentioned in central European literature without efficacy data.
Treatment specifics
How many leeches, where they are placed, how long a session lasts, and whether to repeat are clinical decisions made by a qualified provider under institutional protocol — not something to self-administer. Discuss the specifics with a clinician experienced in medicinal leech therapy. (Clinicians: switch the audience selector in the top bar to “Clinician” to view protocol detail.)
Contraindications
- Active anticoagulant therapy (warfarin INR >2.0, DOACs, heparin)
- Hemophilia or other bleeding disorder
- Severe anemia (Hb <10 g/dL)
- Active bacteremia or sepsis
- Known hypersensitivity to leech salivary proteins
- Pregnancy (relative — first/third trimester)
- Immunocompromised state with severe neutropenia
- Placement directly on lipomatous nodule (absolute)
- Active opioid dependence requiring detoxification first
- Severe morbid obesity with skin maceration at intended site
- Untreated secondary cause of lipomatosis (familial multiple lipomatosis, Madelung)
Related Conditions
Metabolic Syndrome (Investigational Adjunct)
Investigational adjunct to lifestyle modification in metabolic syndrome; small case series only; weight loss, dietary modification, and pharmacotherapy remain primary.
Hashimoto's Thyroiditis (Investigational Cervical Adjunct)
Highly investigational adjunct in stable Hashimoto's thyroiditis; case reports only; levothyroxine replacement remains primary.
Myalgic Encephalomyelitis / Chronic Fatigue Syndrome (Investigational Adjunct)
Investigational adjunct for ME/CFS symptom management; pacing strategies, post-exertional malaise avoidance, and individualized supportive care remain primary; graded exercise therapy is no longer recommended per updated NICE guidance.
Stage III Postsurgical Lymphedema (Highly Investigational Adjunct)
Highly investigational adjunct for advanced postsurgical lymphedema; complete decongestive therapy and (selectively) surgical options (LVA, VLNT) remain evidence-based.